
|Videos|December 17, 2014
Providing Optimal Care for Prostate Cancer
Advertisement
Episodes in this series

For High-Definition, Click
In this segment, Gary M. Kirsh, MD, describes his practice’s model of coordinating care of each patient by having physicians provide sub-specialty care. For example, if a patient develops metastases, he may be switched to a different doctor—a specialist in treatment and managing metastases. Sanford J. Siegel, MD, shares that his practice takes a similar approach, but uses physician assistants. He sees the effectiveness of using these physician assistants, who are adept at running clinics in a protocol-driven manner.
Advertisement
Related to this article

Lutetium Lu 177 vipivotide tetraxetan showed a median overall survival of 13.1 months in the French PSMA-REACH mCRPC cohort.

Praful Ravi, MB, BChir, MRCP, discusses the LASER futility readout, PSMA heterogeneity in clear cell RCC, and next steps for radiopharmaceuticals.

Daniel Heng, MD, MPH, FRCPC, discusses data from LITESPARK-011, second-line RCC sequencing, and managing belzutifan-associated anemia and hypoxia.

The FDA approved talazoparib plus enzalutamide in HRR-mutated prostate cancer, ivonescimab improved survival in biliary tract cancer, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The top 5 OncLive TV videos of the week cover insights in endometrial cancer, mCRPC, germ cell tumors, melanoma, and HNSCC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Amivantamab and Hyaluronidase for Metastatic HNSCC
2
BCG Optimization Becomes a Priority as Durvalumab Gains a Role in High-Risk NMIBC
3
Dr Skoulidis on Divarasib vs Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC
4
Dr Cai on the Rationale for Evaluating Rocbrutinib Plus R-CHOP in Non-GCB DLBCL and MCL
5










